Poll: Do You Agree with the FDA's Decision to Pull Avastin?

Article

This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy.

Everyone wants the best treatment available when it comes to cancer, breast cancer is no different. This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy. Avastin is still available for other types of cancer but because it is no longer approved for breast cancer insurance companies will not cover the approximately $8000.00 per month it costs. This puts breast cancer treatment out of reach for many women who say this was working for them.

Related Videos
Shocking maternal health findings from 2023 March of Dimes report card | Image Credit: marchofdimes.org
The importance of maternal vaccination | Image Credit: nfid.org.
Expert on OAB
Expert on OAB
How to address sexual dysfunction during menopause | Image Credit: health.usnews.com
Hot flashes poorly impact sleep quality | Image Credit: intimmedicine.com
Experts on OAB
Expert on OAB
Expert on OAB
© 2023 MJH Life Sciences

All rights reserved.